News

Moexipril HCl is the generic equivalent of Univasc tablets, marketed by Schwarz. The product is indicated for the treatment of patients with hypertension. Reportedly, in March 2010, Glenmark

Orexigen Therapeutics said that the NDA for Contrave is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over

Sym004 is composed of two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies targeting different nonoverlapping EGFR epitopes. Symphogen said that the Phase 1/2 clinical trial is an open-label,

Cubist Pharma made this decision after reviewing top line efficacy and safety data from the CB-500,929 Phase 2 Conserv 1 and Conserv 2 trials. Cubist Pharma said that

The complete response letter identifies issues that would have to be addressed before re-submission, including the generation of additional clinical data. ProStrakan plans to meet with the FDA

The Phase III safety study is randomised, double-blinded trial comparing the safety profile of CIP- Isotretinoin to an FDA-approved, commercially available isotretinoin product. The study is currently being

Reportedly, Vivus failed to start the Luramist Phase 3 trial by the outside date of 1 April 2010 that was set by the independent arbitration panel, convened by

In addition, as per the agreement, Biohit will cross-promote BioCision’s thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes. Michelle Nemits, vice president of sales and

Revenue management solutions are part of McKesson’s comprehensive portfolio of physician solutions designed to reduce time spent on administrative tasks and streamline practice operations. As the source for